Clinical Trial Update: A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and PK/PD of OriCAR-017 in subjects with relapsed/refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• OriCAR-017

Snippet

Sponsor: OriCell Therapeutics Co., Ltd. | Conditions: Neoplasms, Plasma Cell, Neoplasms by Histologic Type | Phase 1 | Status: RECRUITING